Clinical Trial Update: An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ABT-SLV176 for the treatment of hypogonadism/testosterone deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism
• Testosterone Deficiency

Drugs mentioned

• ABT-SLV176

Snippet

Sponsor: AbbVie | Conditions: Hypogonadism, Testosterone Deficiency | Phase 3 | Status: WITHDRAWN